Shahbaz Aman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shahbaz Aman has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Narinder Kaur
Department of Microbiology, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, India
6 shared publications Priya Koundal
Department of Biochemistry, MM Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India
4 shared publications- Shalini Shriwastav
Department of Microbiology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala- Haryana, India
4 shared publications - Jai Dev
Department of Microbiology, M.M. Institute of Medical Science and Research, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana
3 shared publications - Mahmudul Hassan
Center for interdisciplinary biomedical research, Adesh University, Bhatinda, Punjab, India
3 shared publications Shakeel Ahmed Mohammed
Department of Biosciences & Technology and Central Research Cell, MM Engineering College, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana, 133207, India
3 shared publications
Latest Publications
- Open Access
- 5 July 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
Proteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapy
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and damage. Early clinical diagnosis is crucial for effective intervention but presents significant challenges due to an initial asymptomatic inflammatory phase. Main body: Anti-citrullinated-protein antibodies (ACPA) and rheumatoid factor (RF) detection have been useful in early RA diagnosis, but their reliability is debatable as they are often non-specific. This has prompted a quest for alternative, more robust biomarkers. Researchers have turned to advanced proteomic and glycosylation analyses of biological fluids (e.g., synovial fluid, plasma and serum) and tissues using techniques such as MALDI-MS, Q-TOF, and SELDI-TOF. These approaches may offer a comprehensive approach to scrutinize a range of biomolecules as potential RA biomarkers, from citrullinated-proteins and peptides to novel potential protein biomarkers such as thymosin, macrophage-capping protein, calgranulins, and serum amyloid-A. Further, proteomics-based approaches have the ability to specifically monitor changes in the RA proteome (e.g., glycosylated VCAM1/SEMA4D proteins and GFAP/A1BG auto-antibodies) to unearth potential diagnostic and prognostic candidates. Disease monitoring in response to anti-rheumatic drugs using treatment-responsive markers, such as S100A8/A9 heterocomplex and leucine-rich alpha-2 glycoprotein, is another application of proteomics-based technologies. Conclusion: In view of the significance of prediction, early diagnosis and monitoring of RA symptomatology, this review discusses the potential utilities of proteinaceous species as proteomics-based biomarkers that may provide insights into disease mechanisms and offer potential avenues for personalized therapeutic interventions to revolutionize RA management.
- 5 July 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
Open AccessProteomic and glycosylation biomarkers in rheumatoid arthritis: advancing early diagnosis and precision therapy
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint inflammation and damage. Early clinical diagnosis is crucial for effective intervention but presents significant challenges due to an initial asymptomatic inflammatory phase. Main body: Anti-citrullinated-protein antibodies (ACPA) and rheumatoid factor (RF) detection have been useful in early RA diagnosis, but their reliability is debatable as they are often non-specific. This has prompted a quest for alternative, more robust biomarkers. Researchers have turned to advanced proteomic and glycosylation analyses of biological fluids (e.g., synovial fluid, plasma and serum) and tissues using techniques such as MALDI-MS, Q-TOF, and SELDI-TOF. These approaches may offer a comprehensive approach to scrutinize a range of biomolecules as potential RA biomarkers, from citrullinated-proteins and peptides to novel potential protein biomarkers such as thymosin, macrophage-capping protein, calgranulins, and serum amyloid-A. Further, proteomics-based approaches have the ability to specifically monitor changes in the RA proteome (e.g., glycosylated VCAM1/SEMA4D proteins and GFAP/A1BG auto-antibodies) to unearth potential diagnostic and prognostic candidates. Disease monitoring in response to anti-rheumatic drugs using treatment-responsive markers, such as S100A8/A9 heterocomplex and leucine-rich alpha-2 glycoprotein, is another application of proteomics-based technologies. Conclusion: In view of the significance of prediction, early diagnosis and monitoring of RA symptomatology, this review discusses the potential utilities of proteinaceous species as proteomics-based biomarkers that may provide insights into disease mechanisms and offer potential avenues for personalized therapeutic interventions to revolutionize RA management.
- Open Access
Global Proteome Remodelling in Rhodococcus jialingiae RS1 to Decipher its Plant Growth-Promoting and Biofertilizer Properties: Gene Identification for Transgenics
1. Abiotic stresses like nitrogen deficiency and soil salinity are major factors contributing to low crop yields. The use of selective biofertilizers alleviates both types of stress. In this study, we investigated the biofertilizer activity and plant growth-promoting properties (PGP) of Rhodococcus jialingiae RS1 through cytosolic proteome remodelling. We cultured RS1 under two conditions, i) without and ii) with 6% NaCl, in nitrogen-deficient defined Burk’s medium. Under dual stress of nitrogen limitation and salt stress, Orbitrap LC-MS/MS proteomics revealed one-quarter of the proteome remodelling, particularly the upregulation of ribosomal synthesis and protein repair systems. As expected, we found high expression of EctC, an ectoine synthase, a key enzyme in osmolyte biosynthesis. Additionally, ribosomal and translational-associated factors, including RpsL, RpsS, RpsT, RpsR1, RplV, RplL, RplA, and elongation factor Tuf, were highly expressed, suggesting enhanced translational fidelity under dual stress. High levels of DNA protection protein, Dps suggest dual stress may lead to DNA damage. Upregulation of chaperones, environmental sensors (KinE), and redox transcriptional factors like WhiB3, Hsp18, AhpC, and MetE suggests protein misfolding and oxidative stress. Metabolic modulations were evident through high expression of IlvA, NAD-dependent glutamate dehydrogenase, lipid/envelope-remodelling enzymes, cutinase/esterases, lipases, endopeptidases like NlpC/P60 and transport systems. In contrast, proteins involved in urease structural components (urea-G), nitrogen regulators and ammonium transporters (GlnK and Amt) were downregulated. Dual stress may lead to an energy crisis, prompting strategic shifts away from high-ATP-dependent ureolytic nitrogen-scavenging pathways towards lower-energy nitrogen-assimilating routes, such as IlvA-mediated deamination and NAD-dependent glutamate dehydrogenation. Genetic manipulations of the above-mentioned genes or their homologues across the genera of microbes, plants, and crops may enhance resilience to abiotic stresses. Our studies reveal stress-responsive genes and biochemical pathways that could be used to improve transgenic efficacy in nitrogen-limited, saline soil and other (a)biotic stresses. Global Proteome Profiling of Rhodococcus jialingiae RS1 to Develop Transgenics:
Open AccessGlobal Proteome Remodelling in Rhodococcus jialingiae RS1 to Decipher its Plant Growth-Promoting and Biofertilizer Properties: Gene Identification for Transgenics
1. Abiotic stresses like nitrogen deficiency and soil salinity are major factors contributing to low crop yields. The use of selective biofertilizers alleviates both types of stress. In this study, we investigated the biofertilizer activity and plant growth-promoting properties (PGP) of Rhodococcus jialingiae RS1 through cytosolic proteome remodelling. We cultured RS1 under two conditions, i) without and ii) with 6% NaCl, in nitrogen-deficient defined Burk’s medium. Under dual stress of nitrogen limitation and salt stress, Orbitrap LC-MS/MS proteomics revealed one-quarter of the proteome remodelling, particularly the upregulation of ribosomal synthesis and protein repair systems. As expected, we found high expression of EctC, an ectoine synthase, a key enzyme in osmolyte biosynthesis. Additionally, ribosomal and translational-associated factors, including RpsL, RpsS, RpsT, RpsR1, RplV, RplL, RplA, and elongation factor Tuf, were highly expressed, suggesting enhanced translational fidelity under dual stress. High levels of DNA protection protein, Dps suggest dual stress may lead to DNA damage. Upregulation of chaperones, environmental sensors (KinE), and redox transcriptional factors like WhiB3, Hsp18, AhpC, and MetE suggests protein misfolding and oxidative stress. Metabolic modulations were evident through high expression of IlvA, NAD-dependent glutamate dehydrogenase, lipid/envelope-remodelling enzymes, cutinase/esterases, lipases, endopeptidases like NlpC/P60 and transport systems. In contrast, proteins involved in urease structural components (urea-G), nitrogen regulators and ammonium transporters (GlnK and Amt) were downregulated. Dual stress may lead to an energy crisis, prompting strategic shifts away from high-ATP-dependent ureolytic nitrogen-scavenging pathways towards lower-energy nitrogen-assimilating routes, such as IlvA-mediated deamination and NAD-dependent glutamate dehydrogenation. Genetic manipulations of the above-mentioned genes or their homologues across the genera of microbes, plants, and crops may enhance resilience to abiotic stresses. Our studies reveal stress-responsive genes and biochemical pathways that could be used to improve transgenic efficacy in nitrogen-limited, saline soil and other (a)biotic stresses. Global Proteome Profiling of Rhodococcus jialingiae RS1 to Develop Transgenics:
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3360-3369
Nacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens
The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical in vitro and in vivo studies demonstrate that NAC, when combined with β-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-β-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by β-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad β-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections.
- 8 May 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (6) , 3360-3369
Open AccessNacubactam: a review on mechanistic insights and therapeutic promise for combating β-lactam resistance among multidrug-resistant Gram-negative pathogens
The unprecedented rise of antimicrobial resistance has substantially compromised the efficacy of β-lactam antibiotics, once the cornerstone of bacterial infection management, posing a major challenge to modern medicine. β-Lactams exert their antibacterial effect by inhibiting penicillin-binding proteins (PBPs) involved in cell wall synthesis; however, resistance mechanisms including porin alterations, PBP mutations, β-lactamase production, and efflux systems increasingly limit their clinical utility. In response, the development of β-lactamase inhibitors (BLIs) has become a critical strategy, with diazabicyclooctanes such as nacubactam (NAC) representing a mechanistically distinct advancement. NAC is a non-β-lactam BLI that exhibits a unique multi-modal mechanism of action encompassing inhibition of serine β-lactamases (Ambler classes A, C, and selected D), direct binding to penicillin-binding protein 2 (PBP2), and enhancement of partner β-lactam activity, including in certain β-lactamase-negative strains. Preclinical in vitro and in vivo studies demonstrate that NAC, when combined with β-lactams such as cefepime, aztreonam, or meropenem, produces substantial reductions in minimum inhibitory concentrations against multidrug-resistant Gram-negative pathogens, including carbapenemase-producing and metallo-β-lactamase (MBL)-coexpressing Enterobacterales. PBP2 targeting contributes to characteristic morphological changes and intrinsic antibacterial activity, resulting in synergistic cell wall disruption when used in combination regimens. Early clinical data from phase I studies indicate that NAC is generally well tolerated, with favorable pharmacokinetic properties and no serious safety concerns reported to date. Nevertheless, NAC lacks direct activity against class B MBLs and exhibits limited efficacy against certain non-fermenting Gram-negative organisms. Moreover, resistance mediated by β-lactamase or PBP2 alterations remains a potential concern. Importantly, robust human efficacy data from phase II and III clinical trials are currently limited. NAC represents a promising investigational BLI with a mechanistically innovative profile and broad β-lactam-potentiating capacity. While preclinical and early clinical findings support its translational potential, further clinical validation is required to define its therapeutic role, optimal combinations, and long-term impact in the management of multidrug-resistant Gram-negative infections.
- Open Access
- 31 March 2026
- Published by Advanced Research Publications in Journal of Communicable Diseases
- Vol. 58 (1) , 104-119
Prevalence, Proteomic Profiling and In Silico Allergenicity Prediction of Cytosolic Proteins of Aspergillus fumigatus Obtained from Respiratory Patients
- 31 March 2026
- Published by Advanced Research Publications in Journal of Communicable Diseases
- Vol. 58 (1) , 104-119
Open AccessPrevalence, Proteomic Profiling and In Silico Allergenicity Prediction of Cytosolic Proteins of Aspergillus fumigatus Obtained from Respiratory Patients
- Open Access
- 15 January 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 25 (1)
Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis
Aspergillus fumigatus is a significant fungal pathogen responsible for allergic bronchopulmonary aspergillosis (ABPA), a global respiratory disease characterized by high morbidity and mortality. Accurate diagnosis of ABPA remains challenging due to the overlap of clinical and radiological features with other respiratory infections. This study aimed to identify A. fumigatus specific antigens and epitopes to advance immunodiagnostic and immunotherapeutic strategies for ABPA. Clinically confirmed ABPA patients were recruited, and their sera were tested for immunoreactivity against A. fumigatus crude and recombinant allergens. Proteomic analysis was done by employing two-dimensional electrophoresis (2DE) immunoblotting of A. fumigatus cytosolic fractions using sera from 10 individual patients. IgE-reactive spots identified via Q-TOF mass spectrometry revealed 18 allergenic proteins. Among these, two known allergens (Asp-f12 and Asp-f22) and three predicted allergens (sorbitol/xylulose-reductase, Hsp70-chaperone Hsp88, and Hsp70) exhibited cross-reactivity with allergens from other fungi. Notably, 13 allergenic proteins demonstrated significant immunoreactivity specific to ABPA patient sera. In silico epitope analysis identified 9 A. fumigatus specific B-cell and 4 T-cell epitopes with antigenic potential. Molecular docking studies confirmed the binding of representative B-cell and T-cell epitopes to their respective receptors (B-cell receptor and MHC-II complex), demonstrating receptor-specific interactions. These findings highlight pathogen-specific allergens and epitopes that could serve as valuable resources for developing targeted immunodiagnostic and immunotherapeutic tools. This approach may improve the clinical management of ABPA and help reduce its global disease burden. Graphical Abstract
- 15 January 2026
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 25 (1)
Open AccessPathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis
Aspergillus fumigatus is a significant fungal pathogen responsible for allergic bronchopulmonary aspergillosis (ABPA), a global respiratory disease characterized by high morbidity and mortality. Accurate diagnosis of ABPA remains challenging due to the overlap of clinical and radiological features with other respiratory infections. This study aimed to identify A. fumigatus specific antigens and epitopes to advance immunodiagnostic and immunotherapeutic strategies for ABPA. Clinically confirmed ABPA patients were recruited, and their sera were tested for immunoreactivity against A. fumigatus crude and recombinant allergens. Proteomic analysis was done by employing two-dimensional electrophoresis (2DE) immunoblotting of A. fumigatus cytosolic fractions using sera from 10 individual patients. IgE-reactive spots identified via Q-TOF mass spectrometry revealed 18 allergenic proteins. Among these, two known allergens (Asp-f12 and Asp-f22) and three predicted allergens (sorbitol/xylulose-reductase, Hsp70-chaperone Hsp88, and Hsp70) exhibited cross-reactivity with allergens from other fungi. Notably, 13 allergenic proteins demonstrated significant immunoreactivity specific to ABPA patient sera. In silico epitope analysis identified 9 A. fumigatus specific B-cell and 4 T-cell epitopes with antigenic potential. Molecular docking studies confirmed the binding of representative B-cell and T-cell epitopes to their respective receptors (B-cell receptor and MHC-II complex), demonstrating receptor-specific interactions. These findings highlight pathogen-specific allergens and epitopes that could serve as valuable resources for developing targeted immunodiagnostic and immunotherapeutic tools. This approach may improve the clinical management of ABPA and help reduce its global disease burden. Graphical Abstract
- 10 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Schiff Base Metal Complexes as Dual Antimicrobial and Anticancer Agents: Synthesis, Characterization, DFT, and Molecular Docking Investigations
A series of four metal complexes, [CdC 16 H 14 N 6 S 2 Cl 2 ] (1) , [FeC 17 H 22 N 6 OS 2 Cl 3 ] (2) , [ZrC 16 H 20 N 6 O 2 S 2 Cl 2 ] (3), and [MoC 18 H 12 N 6 O 2 S 2 Cl 2 ] (4) were prepared by the Schiff base derived from thiosemicarbazide and p‐chlorobenzaldehyde reacting with their respective metal salts. The synthesized ligand and its metal complexes were characterized using FT‐IR, 1 H NMR, UV–vis, molar conductivity, elemental analyses, and magnetic moment measurements. The antimicrobial potential of these compounds were evaluated against two Gram‐positive bacteria ( Staphylococcus aureus and Enterococcus faecalis ), two Gram‐negative bacteria ( Escherichia coli and Pseudomonas aeruginosa ), and two fungal species ( Fusarium oxysporum and Candida albicans ). The biocompatibility of ligands and metal complexes was assessed using the RBC lysis test. Further, the in vitro anticancer activities of synthesized compounds were evaluated against a breast cancer cell line (MDMB‐231), which revealed complex 1 and 4 as most potent against the cancer cell line. In addition, density functional theory (DFT) simulations were used to optimize the complexes structures, offering further information about their electrical characteristics. To investigate the interaction processes, AutoDock4 was used to perform docking studies on both DNA and Human serum albumin (HSA). Among all, the molybdenum complex exhibited the highest binding affinities toward both DNA and HSA with docking scores of –7.66 and –6.72 kcal/mol, respectively. The novelty of this study lies in the first systematic comparison of Cd(II), Fe(III), Zr(IV), and Mo(VI) complexes of a para‐chlorobenzaldehyde–thiosemicarbazone ligand, establishing new structure–activity relationships supported by docking and biological data.
- 10 January 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (2)
Schiff Base Metal Complexes as Dual Antimicrobial and Anticancer Agents: Synthesis, Characterization, DFT, and Molecular Docking Investigations
A series of four metal complexes, [CdC 16 H 14 N 6 S 2 Cl 2 ] (1) , [FeC 17 H 22 N 6 OS 2 Cl 3 ] (2) , [ZrC 16 H 20 N 6 O 2 S 2 Cl 2 ] (3), and [MoC 18 H 12 N 6 O 2 S 2 Cl 2 ] (4) were prepared by the Schiff base derived from thiosemicarbazide and p‐chlorobenzaldehyde reacting with their respective metal salts. The synthesized ligand and its metal complexes were characterized using FT‐IR, 1 H NMR, UV–vis, molar conductivity, elemental analyses, and magnetic moment measurements. The antimicrobial potential of these compounds were evaluated against two Gram‐positive bacteria ( Staphylococcus aureus and Enterococcus faecalis ), two Gram‐negative bacteria ( Escherichia coli and Pseudomonas aeruginosa ), and two fungal species ( Fusarium oxysporum and Candida albicans ). The biocompatibility of ligands and metal complexes was assessed using the RBC lysis test. Further, the in vitro anticancer activities of synthesized compounds were evaluated against a breast cancer cell line (MDMB‐231), which revealed complex 1 and 4 as most potent against the cancer cell line. In addition, density functional theory (DFT) simulations were used to optimize the complexes structures, offering further information about their electrical characteristics. To investigate the interaction processes, AutoDock4 was used to perform docking studies on both DNA and Human serum albumin (HSA). Among all, the molybdenum complex exhibited the highest binding affinities toward both DNA and HSA with docking scores of –7.66 and –6.72 kcal/mol, respectively. The novelty of this study lies in the first systematic comparison of Cd(II), Fe(III), Zr(IV), and Mo(VI) complexes of a para‐chlorobenzaldehyde–thiosemicarbazone ligand, establishing new structure–activity relationships supported by docking and biological data.
- Open Access
- 17 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8221-8228
Categorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers
Introduction: Rheumatoid arthritis (RA) diagnosis continues to face challenges regarding the specificity and sensitivity of routine serological markers. This study aimed to assess the demographic distribution and serum biomarker profiles of RA patients with varying disease severity in Haryana, India, and to evaluate their diagnostic utility. Methods: A total of 200 participants were enrolled, including 150 RA patients and 50 healthy controls. RA patients were stratified into mild ( n = 50), moderate ( n = 50), and severe ( n = 50) disease categories using the Disease Activity Score-28 (DAS28). Demographic data, body mass index (BMI), and serum levels of rheumatoid factor (RF), anticyclic citrullinated peptide antibodies (anti-CCP), and C-reactive protein (CRP) were measured and statistically analyzed for intergroup comparisons and diagnostic correlations. Results: Female predominance was observed across all RA severity groups, with the highest proportion in the severe category. Biomarker levels (RF, anti-CCP, and CRP) showed significant progressive elevation from mild to severe RA. Statistical analysis demonstrated robust correlations between biomarker titers and disease severity, with anti-CCP exhibiting the highest specificity among individual markers. Combined RF and anti-CCP assessment improved diagnostic accuracy. Chi-square tests revealed significant associations between biomarker profiles and disease severity, supporting their diagnostic relevance. Conclusions: Our findings underscore the clinical significance of combining serological biomarkers to enhance diagnostic precision in RA. The graded increase in biomarker titers across severity levels suggests their potential role in disease stratification and the development of tailored therapeutic strategies.
- 17 October 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 8221-8228
Open AccessCategorization of rheumatoid arthritis into mild, moderate, and severe conditions to discriminate specificity and sensitivity of routine diagnostic serum biomarkers
Introduction: Rheumatoid arthritis (RA) diagnosis continues to face challenges regarding the specificity and sensitivity of routine serological markers. This study aimed to assess the demographic distribution and serum biomarker profiles of RA patients with varying disease severity in Haryana, India, and to evaluate their diagnostic utility. Methods: A total of 200 participants were enrolled, including 150 RA patients and 50 healthy controls. RA patients were stratified into mild ( n = 50), moderate ( n = 50), and severe ( n = 50) disease categories using the Disease Activity Score-28 (DAS28). Demographic data, body mass index (BMI), and serum levels of rheumatoid factor (RF), anticyclic citrullinated peptide antibodies (anti-CCP), and C-reactive protein (CRP) were measured and statistically analyzed for intergroup comparisons and diagnostic correlations. Results: Female predominance was observed across all RA severity groups, with the highest proportion in the severe category. Biomarker levels (RF, anti-CCP, and CRP) showed significant progressive elevation from mild to severe RA. Statistical analysis demonstrated robust correlations between biomarker titers and disease severity, with anti-CCP exhibiting the highest specificity among individual markers. Combined RF and anti-CCP assessment improved diagnostic accuracy. Chi-square tests revealed significant associations between biomarker profiles and disease severity, supporting their diagnostic relevance. Conclusions: Our findings underscore the clinical significance of combining serological biomarkers to enhance diagnostic precision in RA. The graded increase in biomarker titers across severity levels suggests their potential role in disease stratification and the development of tailored therapeutic strategies.
- Open Access
- 1 June 2025
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 19 (2) , 914-929
Aspergillus fumigatus-Associated Disease Spectrum, Virulence Factors, Pathogenicity, and Currently Used Diagnostic Approaches
Aspergillus fumigatus is a pathogenic fungus that causes fatal infectious human disease known as aspergillosis. Fungus A. fumigatus is capable of causing infections in various body parts of humans, but it primarily infects the lungs and causes pulmonary infections known as allergic bronchopulmonary aspergillosis (ABPA). Subsequent dissemination of A. fumigatus into the deeper body parts may also contribute to the development of invasive infections in other vital organs. Therefore, the complexity and spectrum of aspergillosis majorly include allergic and invasive infections. To dominate the human body and escape the human immune system, A. fumigatus produces a number of virulence factors as well as pathogenicity determinants to establish disease. These pathogenic moieties of A. fumigatus includes allergens, toxins, hydrophobins, integrins, mannans/galactomannans, lectins, adherins and many other proteins with unknown functions. Combinatorially, these components make A. fumigatus a successful pathogen for humans, although, additionally the A. fumigatus pathogenicity has also been influenced by the metabolism of nitrogen/amino acids, folate synthesis, metal ions, cell wall biosynthesis as well as protein degradation mechanisms. A number of tools and techniques are being used to provide an accurate and timely laboratory diagnosis of aspergillosis. Such comprehensive tools include microscopic examination, culture, and antigen detection methods, serological assays and molecular techniques (DNA probes and molecular typing), G-test and D-mannitol detection and others. However, identifying fungi and assessing antifungal susceptibility by detecting galactomannans and Aspergillus-DNA are also useful. However, certain limitations exist in determining the circulating biomarkers that can be addressed via upcoming approaches such as lateral flow devices and next-generation sequencing. According to current understandings, the biology and clinical impact of A. fumigatus have been complex; therefore, updated information about virulence mechanisms, clinical manifestations, and diagnosis intricacies is essentially required for effective and better management and treatment of Aspergillus-induced infections.
- 1 June 2025
- Published by Journal of Pure and Applied Microbiology in Journal of Pure and Applied Microbiology
- Vol. 19 (2) , 914-929
Open AccessAspergillus fumigatus-Associated Disease Spectrum, Virulence Factors, Pathogenicity, and Currently Used Diagnostic Approaches
Aspergillus fumigatus is a pathogenic fungus that causes fatal infectious human disease known as aspergillosis. Fungus A. fumigatus is capable of causing infections in various body parts of humans, but it primarily infects the lungs and causes pulmonary infections known as allergic bronchopulmonary aspergillosis (ABPA). Subsequent dissemination of A. fumigatus into the deeper body parts may also contribute to the development of invasive infections in other vital organs. Therefore, the complexity and spectrum of aspergillosis majorly include allergic and invasive infections. To dominate the human body and escape the human immune system, A. fumigatus produces a number of virulence factors as well as pathogenicity determinants to establish disease. These pathogenic moieties of A. fumigatus includes allergens, toxins, hydrophobins, integrins, mannans/galactomannans, lectins, adherins and many other proteins with unknown functions. Combinatorially, these components make A. fumigatus a successful pathogen for humans, although, additionally the A. fumigatus pathogenicity has also been influenced by the metabolism of nitrogen/amino acids, folate synthesis, metal ions, cell wall biosynthesis as well as protein degradation mechanisms. A number of tools and techniques are being used to provide an accurate and timely laboratory diagnosis of aspergillosis. Such comprehensive tools include microscopic examination, culture, and antigen detection methods, serological assays and molecular techniques (DNA probes and molecular typing), G-test and D-mannitol detection and others. However, identifying fungi and assessing antifungal susceptibility by detecting galactomannans and Aspergillus-DNA are also useful. However, certain limitations exist in determining the circulating biomarkers that can be addressed via upcoming approaches such as lateral flow devices and next-generation sequencing. According to current understandings, the biology and clinical impact of A. fumigatus have been complex; therefore, updated information about virulence mechanisms, clinical manifestations, and diagnosis intricacies is essentially required for effective and better management and treatment of Aspergillus-induced infections.
- Open Access
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2118-2132
Antimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens
Antimicrobial peptides (AMPs) are varied naturally occurring compounds that are crucial to the innate immune system among several organisms. These peptides are effective against various bacteria, viruses, fungus, and cancer cells. Alternative therapeutic options are becoming more important as drug-resistant diseases become a global concern nowadays. AMPs unique modes of action and benefits over traditional antibiotics make them potential candidates for improving drug-resistant disease treatment. The capacity to target microbial membranes, alter intracellular processes, and bypass resistance systems distinguishes AMPs, making it challenging to develop resistance. This review examines how AMPs can combat drug-resistant bacteria and also, emphasizes on the broad-spectrum antibacterial properties of AMPs and their many mechanisms like, AMPs can permeabilize bacterial membranes, limit biofilm formation, and alter immune responses, making them promising therapeutics for infections that defy conventional treatments. As antibiotic resistance threatens global health, AMPs offer a possible path for next-generation antimicrobials. Export
- 27 March 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (4) , 2118-2132
Open AccessAntimicrobial peptides: a promising frontier to combat antibiotic resistant pathogens
Antimicrobial peptides (AMPs) are varied naturally occurring compounds that are crucial to the innate immune system among several organisms. These peptides are effective against various bacteria, viruses, fungus, and cancer cells. Alternative therapeutic options are becoming more important as drug-resistant diseases become a global concern nowadays. AMPs unique modes of action and benefits over traditional antibiotics make them potential candidates for improving drug-resistant disease treatment. The capacity to target microbial membranes, alter intracellular processes, and bypass resistance systems distinguishes AMPs, making it challenging to develop resistance. This review examines how AMPs can combat drug-resistant bacteria and also, emphasizes on the broad-spectrum antibacterial properties of AMPs and their many mechanisms like, AMPs can permeabilize bacterial membranes, limit biofilm formation, and alter immune responses, making them promising therapeutics for infections that defy conventional treatments. As antibiotic resistance threatens global health, AMPs offer a possible path for next-generation antimicrobials. Export